Anjali Katyal Nath, Ph.D.
Title Assistant Professor of Medicine Institution Beth Israel Deaconess Medical Center Address Beth Israel Deaconess Medical Center
330 Brookline Ave
Boston MA 02215
|
|
Overview
Research Focus:
Our lab works at the interface of human genetics and chemistry. We systematically identify connections between genes and the human biology they regulate through the integration of multiomic human datasets. The overarching goals of these analyses are to determine the function of understudied genes and to identify novel druggable targets. We then use the tools of chemical biology in combination with zebrafish genetic models to dissect the molecular mechanisms of these associations and to identify lead compounds. Our overarching goal is to develop small molecules that modulate the activity of cardiometabolic disease associated genes.
Lab Website:
https://research.bidmc.org/anjali-nath-lab/
BIDMC's Division of Cardiovascular Medicine:
https://www.bidmc.org/research/research-by-department/medicine/cardiovascular-medicine/basic-cardiology-research/nath-lab
Apply to join our group:
Send your research interests, curriculum vitae, and contact information for three references to anath1(AT)bidmc(DOT)harvard(DOT)edu
Research
The research activities and funding listed below are automatically derived from
NIH ExPORTER and other sources, which might result in incorrect or missing items.
Faculty can
login
to make corrections and additions.
-
R21HG010392
(NATH, ANJALI K.)
Sep 1, 2019 - Mar 30, 2023
Illuminating the Understudied Druggable Kinome through Human Phenotypes and Model Organisms
Role Description: Kinases are enzymes that regulate every aspect of cellular activity. However, many human kinases remain
poorly characterized. Here we systematically identify connections between these understudied kinases and the
human biology they regulate through the integration of genomics, proteomics and metabolomics data. These biochemical signatures will highlight potential new metabolic pathways regulated by kinase biology that can then be validated and studied by genetic manipulation in model systems. Successful completion of this project will provide opportunities to understand the biological functions of understudied kinases and will provide novel mechanistic insights into the biology they regulate.
Role: Principal Investigator
-
U54NS112107
(GERSZTEN, ROBERT)
Jul 1, 2019 - Jun 30, 2024
Metabolic Phenotyping and Pharmocokinetics Core
Role Description: The Core leverages a robust LC-MS/MS-based platform to: 1) Perform detailed pharmacokinetic (PK) studies of countermeasures; 2) Identify metabolic surrogates that track with the efficacy of countermeasures, as well as unanticipated off-target effects; 3) Identify very early markers of cyanide toxicity or persistent changes after prior transient exposure so that countermeasures can be instituted at the earliest possible juncture; 4) Identify the broad spectrum of metabolic derangements secondary to cyanide toxicity thus highlighting enzymes or metabolites for therapeutic intervention.
-
U54NS112107
(MACRAE, CALUM)
Jul 1, 2019 - Jun 30, 2024
Advancing Novel Cyanide Countermeasures
Role Description: In prior work within our consortium, we have discovered new compound classes that can counteract the effect of cyanide. Foremost among these are the multivalent cyanide scavenger hexachloroplatinate and the metabolic modulator glyoxylate, but several additional next-generation compounds are in the pipeline. These discoveries pave the way for development of cyanide countermeasures that are fundamentally different from existing countermeasures and have the potential to transform our ability to respond to cyanide exposures. This new U54 will focus on translating these discoveries into optimized, validated leads meeting the formal requirements for advanced development and clinical deployment.
-
R01HL132320
(GERSZTEN, ROBERT E)
Jul 1, 2016 - Apr 30, 2021
Proteomic Pathway Discovery in Cardiovascular Disease
Role Description: The major goal of this project is to use a novel aptamer-based proteomic platform to identify new biomarkers of cardiovascular disease.
Role: Faculty Participant
-
U54NS079201
(MACRAE, CALUM A.)
Sep 30, 2012 - Aug 31, 2018
A Discovery and Development Pipeline for Cyanide Countermeasures
Role Description: The goals of this multi-center project are to create a pipeline of scalable technologies to discover novel cyanide countermeasures, to screen large chemical libraries for novel cyanide countermeasures, to optimize initial hits for activity in vivo, and to test these lead compounds in validated mouse and rabbit models of cyanide toxicity.
-
2012A051526
(NATH, ANJALI K)
Sep 1, 2012 - Aug 31, 2013
MGH ECOR Tosteson Postdoctoral Fellowship Award
Chemical and Genetic Dissection of the Role of Mitochondrial Phosphorylation Events in Pancreatic Beta Cell Biology
Role Description: The goal of this project is to determine the function of a poorly annotated phosphatase, PTPMT1, and to gain deeper insight into the role of mitochondrial phosphorylation in the regulation of beta cell biology.
Role: Principal Investigator
Bibliographic
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.